CULLINAN THERAPEUTICS, INC. Operating Lease Right-of-Use Assets
CULLINAN THERAPEUTICS, INC. (CGEM) had Operating Lease Right-of-Use Assets of $2.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $2.23M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.44M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $2.63M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.05M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $2.23M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.44M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.63M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.18M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.55M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.67M 10-K · filed 2026-03-10 |
| 2024-09-30 | $2.02M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $2.12M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.34M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.54M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.92M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $3.50M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.82M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.13M 10-K · filed 2024-03-14 |
| 2022-09-30 | $4.50M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.07M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $1.19M 10-Q · filed 2022-05-16 |
| 2022-01-01 | $1.31M 10-K · filed 2023-03-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |